Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer
一项针对晚期胰腺癌或结直肠癌患者的BMS-813160(一种CCR2/5双重拮抗剂)联合化疗或纳武利尤单抗的1b/2期研究
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2024-011284
Le, Dung T; Folprecht, Gunnar; Varghese, Anna M; Gutierrez, Martin; Noel, Marcus; Trikalinos, Nikolaos A; Chen, Eric; Dayyani, Farshid; Davis, S Lindsey; Ma, Wen Wee; BasuMallick, Atrayee; Garrido-Laguna, Ignacio; Osawa, Mayu; O'Brien, Shaun; Novosiadly, Ruslan D; Xu, Ke; Greenawalt, Danielle M; Dutta, Santanu; Twyman Saint Victor, Christina; Lenz, Heinz-Josef